Cargando…

1220. Comparing Breakthrough Fungal Infections in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients Receiving Prophylaxis with Different Azoles

BACKGROUND: Posaconazole is recommended for primary prophylaxis in neutropenic patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) receiving induction chemotherapy. Despite prophylaxis, breakthrough invasive fungal infections (bIFIs) still arise. Initiating posaconazole is n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Catherine, Tverdek, Frank P, Escobar, Zahra, Liu, Catherine, Simmons, William F, Bui, Hanh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677763/ http://dx.doi.org/10.1093/ofid/ofad500.1060

Ejemplares similares

2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
por: Bose, Prithviraj, et al.
Publicado: (2019)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
por: Jensen, Oda, et al.
Publicado: (2022)

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

742. Breakthrough Invasive Fungal Infections with Isavuconazonium Sulfate versus Voriconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia (AML) who Received Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
por: Steensma, David P., et al.
Publicado: (2016)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

1150. Breakthrough Invasive Fungal Disease (IFD) in Patients with Acute Myeloid Leukemia (AML)
por: Wasylyshyn, Anastasia, et al.
Publicado: (2020)

971. Breakthrough Invasive Fungal Infections (IFI) in Acute Leukemia (AL) Patients Receiving Antifungal Prophylaxis
por: Wasylyshyn, Anastasia, et al.
Publicado: (2018)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
por: Loke, Justin, et al.
Publicado: (2023)

Age-related epigenetic drift in the pathogenesis of MDS and AML
por: Maegawa, Shinji, et al.
Publicado: (2014)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
por: Johnson, Lisa, et al.
Publicado: (2023)

American Society of Hematology 2020 Podcast Collection: MDS and AML
por: Almeida, António
Publicado: (2021)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
por: Hoff, Fieke W., et al.
Publicado: (2023)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
por: Bhatnagar, Udit Bhaskar, et al.
Publicado: (2016)

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
por: Uy, Geoffrey L., et al.
Publicado: (2016)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
por: Raza, Azra, et al.
Publicado: (2020)

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party
por: Kim, Da Jung, et al.
Publicado: (2017)

1301. Breakthrough Invasive Fungal Infections based on CYP2C19 Levels in Patients Who were on Voriconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) undergoing Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplantation Do Not Fit All: Adjusting BuCy2 in Mexico to Improve Outcomes in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
por: León-Rodríguez, Eucario, et al.
Publicado: (2022)

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML
por: Przychodzen, Bartlomiej, et al.
Publicado: (2017)

Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
por: Menshawy, Nadia El, et al.
Publicado: (2020)

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
por: Rio-Machin, Ana, et al.
Publicado: (2020)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
por: Chang, Lixian, et al.
Publicado: (2022)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oue1gtnkr6ucnkjaof0ib6l9ne